Multicenter phase II study of bendamustine for relapsed or refractory indolent B‐cell non‐Hodgkin lymphoma and mantle cell lymphoma
暂无分享,去创建一个
M. Ogura | K. Tobinai | T. Uchida | N. Uike | I. Choi | K. Ishizawa | K. Itoh | K. Ando | H. Nagai | Takashi Watanabe | N. Uoshima | K. Ohmachi | K. Usuki | Y. Terui | N. Kubota | J. Yamamoto
[1] M. Czuczman,et al. Bendamustine is effective therapy in patients with rituximab‐refractory, indolent B‐cell non‐Hodgkin lymphoma , 2009, Cancer.
[2] A. Tulpule,et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] K. Karube,et al. Distribution of malignant lymphoma in Japan: Analysis of 2260 cases, 2001–2006 , 2008, Pathology international.
[4] J. Friedberg,et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Jacques Corbeil,et al. Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating Agents , 2008, Clinical Cancer Research.
[6] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] P. Solal-Céligny,et al. Follicular lymphoma international prognostic index , 2006, Blood.
[8] R. Fisher,et al. New treatment options have changed the survival of patients with follicular lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Michael E. Williams,et al. Biology and therapy of mantle cell lymphoma , 2005, Current opinion in oncology.
[10] J. Ferlay,et al. Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.
[11] M. Czuczman,et al. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] L. Bergmann,et al. In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia , 2002, Leukemia.
[13] M. Seto,et al. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. , 2000, Blood.
[14] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] D. Strumberg,et al. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines , 1996, Anti-cancer drugs.
[16] A. Hagenbeek,et al. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] B. Nathwani,et al. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. , 1995, Blood.
[18] D. Tormey,et al. The Eastern Cooperative Oncology Group , 1994 .
[19] S. Horning. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. , 1993, Seminars in oncology.
[20] S. Rosenberg. Karnofsky memorial lecture. The low-grade non-Hodgkin's lymphomas: challenges and opportunities. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] E. McFadden,et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.
[22] A. Gellhorn,et al. Laboratory evaluation of a new nitrogen mustard, 2-[di-(2-chloroethyl)amino-methyl]benzimidazole, and of other 2-chloroethyl compounds. , 1957, Cancer research.
[23] 豊 木村,et al. 胃癌手術におけるCommon Terminology Criteria for Adverse Events v3.0を利用した合併症の評価 , 2009 .
[24] C. Catoi,et al. TUMORS OF HEMATOPOIETIC AND LYMPHOID TISSUES , 2007 .
[25] 渡邉 隆. What's going on 造血器腫瘍 Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ. J Clin Oncol. 2004;22:4659-64. PMID:15483 , 2005 .
[26] S. Boehrer,et al. In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine. , 2001, Haematologica.
[27] L. Gordon,et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.